Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > All comers dose and safety vs targeting high sortlin express

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jul 28, 2022 11:04am

75 Views

Post# 34856963

RE:RE:RE:RE:All comers dose and safety vs targeting high sortlin express

They have to do some learning before they do some selecting.

LouisW wrote: Agreed. They have to select the patient according the SORT1 expression level. TH cannot let the propability to determine the fate. Unless they observe almost everyone express high SORT1.

Immunomedics didnt select the patient prior to conductig the larger trial since almost all (88%) of the archival tumor samples in paraffin from these patients in earlier trial expressed relatively high

levels of Trop-2 by IHC, so they said pretherapy biomarkerassessment for patient selection is not required.